SGLT2 inhibitors also reduced the composite of cardiovascular death or hospitalization for heart failure by 29–31% in patients with CKD with or without T2DM, CVD or a history of HF (25, 26). This evidence concerns the gene SLC5A2 and chronic kidney disease.